Business Model & Revenue
Equillium is a clinical-stage biopharmaceutical company developing novel therapeutics for severe immuno-inflammatory diseases. The company's business model centers on advancing proprietary drug candidates through clinical development, with the goal of either obtaining regulatory approval for commercialization or partnering with larger pharmaceutical companies for development and commercialization rights.
Revenue Streams:
- Currently minimal revenue ($4.4M TTM), primarily from collaboration arrangements
- Future revenue potential from product sales (if approved) or partnership milestones and royalties
Pipeline Assets:
- Itolizumab — Anti-CD6 monoclonal antibody targeting activated T-cells; Phase 3 complete in aGVHD, Phase 2 positive in ulcerative colitis
- EQ101 — Tri-specific cytokine inhibitor (IL-2, IL-9, IL-15); Phase 2 proof-of-concept in alopecia areata
- Oral AhR Modulator — Colon-targeted aryl hydrocarbon receptor modulator; Phase 1 planned
Unit Economics: Pre-revenue; R&D-focused with high cash burn typical of clinical-stage biotech.
Financial Highlights
Full-Year 2025 Results
| Metric | 2025 | 2024 | YoY Change |
|---|---|---|---|
| Revenue | $4.39M | N/A | N/A |
| Net Loss | ($27.5M) | N/A | N/A |
| EPS (TTM) | ($0.57) | N/A | N/A |
| Cash | $14.5M* | N/A | N/A |
*As of March 2025; $50M private placement announced Feb 2026
Quarterly Earnings Beats
| Quarter | Reported EPS | Consensus | Beat % |
|---|---|---|---|
| Q3 2025 | -$0.06 | -$0.19 | 68.4% |
| Q4 2025 | Est. -$0.05 | N/A | N/A |
Balance Sheet Snapshot
| Item | Amount |
|---|---|
| Cash (Mar 2025) | $14.5M |
| Private Placement (Feb 2026) | $50M (gross) |
| Shares Outstanding | 60.9M |
Guidance: Company believes cash sufficient to fund operations into 2027 following $50M raise.
Competitive Landscape
Equillium operates in the immuno-inflammatory therapeutics space, competing with both established players and other clinical-stage biotechs developing novel mechanisms.
Key Competitors:
- Johnson & Johnson (JNJ): Tremfya (guselkumab) approved for ulcerative colitis in Sept 2024; deep commercial resources and established market presence
- AbbVie (ABBV): Humira (adalimumab) franchise; losing patent exclusivity but massive installed base in inflammatory diseases
- ImmunityBio (IBRX): Fellow clinical-stage immunotherapy player; focused on IL-15 pathway
- Adaptimmune Therapeutics (ADAP): T-cell therapy platform; distinct mechanism but overlapping immuno-oncology focus
- Alaunos Therapeutics (TCRT): TCR-engineered T-cell therapies; earlier-stage but competing for similar investor mindshare
Moats:
- Differentiated Mechanism — Anti-CD6 targeting is novel; limited direct competition in pathway
- Multi-Indication Potential — Itolizumab has shown activity in aGVHD, UC, and other inflammatory conditions
- Orphan Drug Designations — Regulatory advantages including market exclusivity periods
- Full Rights Post-Biocon — Complete ownership of itolizumab after partnership termination
Catalysts
-
FDA feedback on EQUATOR study expected May 2026 — could determine BLA path
-
Potential BLA submission H1 2026 if regulatory feedback positive
-
Phase 2 ulcerative colitis data presentation at scientific conference in 2025/2026
-
Phase 1 study initiation for oral AhR modulator
-
Strategic partnership discussions for itolizumab commercialization
Key Risks
- Clinical trial failure risk — Phase 3 data may not support approval without additional studies
- Cash burn continues — company remains unprofitable with no approved products
- Manufacturing uncertainty — Biocon partnership termination removed established manufacturing partner
- Regulatory risk — FDA may require additional trials before accepting BLA
- Competitive pressure — JNJ's Tremfya and established anti-inflammatory agents dominate UC market
Our Thesis
Equillium represents a classic binary biotech bet: all eyes are on itolizumab's regulatory path. The anti-CD6 monoclonal antibody has shown promising data across multiple indications, including 23.3% clinical remission in a Phase 2 ulcerative colitis study and completed Phase 3 evaluation in aGVHD. The company expects FDA feedback in May 2026, with a potential BLA submission in H1 2026 if positive. The terminated Biocon partnership is a double-edged sword—Equillium now owns full rights but lost a commercial manufacturing partner.
Valuation is purely catalyst-driven. At a $107M market cap with $4.4M TTM revenue and continued losses, the stock trades on regulatory outcomes rather than fundamentals. The $50M private placement provides runway through 2027, removing near-term dilution risk. Our $4.00 price target (≈2x current) assumes positive FDA feedback and BLA submission, which could re-rate the stock toward peer valuations for late-stage biotech assets.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.